Human leukocyte antigen – DR isotype presenting SARS-CoV-2 T-cell epitopes (CoVac-1) (HLA-DR/CoVac-1)

HLA-DR molecules presenting CoVac-1 epitopes are peptide-major histocompatibility complex (pMHC) class II structures essential for the induction of T-cell-mediated immunity against SARS-CoV-2. CoVac-1 is a multi-peptide vaccine candidate composed of specific amino acid sequences derived from various viral components, such as the Spike, Nucleocapsid, Membrane, and Envelope proteins, which are optimized for binding to HLA-DR alleles (Walz et al., Nature Communications, 2021). Once these peptides are loaded onto HLA-DR molecules on the surface of professional antigen-presenting cells, they are recognized by the T-cell receptors of CD4+ T-helper cells. This interaction is a critical step in orchestrating a comprehensive immune response, particularly in individuals with impaired B-cell function who cannot produce effective neutralizing antibodies (Heitmann et al., Nature, 2022). The use of multiple conserved epitopes ensures that the immune system can recognize different variants of the virus, potentially providing broader protection than single-antigen vaccines. Clinical development has focused on using this target to protect vulnerable populations, such as cancer patients undergoing B-cell depleting therapies (NCT04546334).

Other names

MHC class II/CoVac-1 peptide complexHLA-DR/SARS-CoV-2 multi-peptide complexCoVac-1 antigen-presenting complexHLA-DR-presented SARS-CoV-2 epitopes

The CoVac-1 vaccine provides synthetic peptides that bind to HLA-DR molecules on antigen-presenting cells; these complexes are then recognized by T-cell receptors on CD4+ T cells, triggering a specific cellular immune response against SARS-CoV-2 (Walz et al., Nature Communications, 2021).